Advertisement
HALO or NTRA or RARE
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HALO’s FA Score shows that 1 FA rating(s) are green whileNTRA’s FA Score has 0 green FA rating(s), and RARE’s FA Score reflects 0 green FA rating(s).
- HALO’s FA Score: 1 green, 4 red.
- NTRA’s FA Score: 0 green, 5 red.
- RARE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HALO’s TA Score shows that 7 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s), and RARE’s TA Score reflects 5 bullish TA indicator(s).
- HALO’s TA Score: 7 bullish, 3 bearish.
- NTRA’s TA Score: 4 bullish, 3 bearish.
- RARE’s TA Score: 5 bullish, 3 bearish.
Price Growth
HALO (@Biotechnology) experienced а -3.25% price change this week, while NTRA (@Medical Specialties) price change was +3.82% , and RARE (@Biotechnology) price fluctuated +9.21% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.46%. For the same industry, the average monthly price growth was +5.98%, and the average quarterly price growth was +2.17%.
Reported Earning Dates
HALO is expected to report earnings on Aug 12, 2025.
NTRA is expected to report earnings on Jul 31, 2025.
RARE is expected to report earnings on Jul 31, 2025.
Industries' Descriptions
@Biotechnology (+9.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+2.46% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| HALO | NTRA | RARE | |
| Capitalization | 6.69B | 11B | 3.51B |
| EBITDA | 705M | -397.8M | -449.9M |
| Gain YTD | 13.470 | 3.449 | -11.659 |
| P/E Ratio | 14.43 | N/A | N/A |
| Revenue | 1.08B | 1.08B | 591M |
| Total Cash | 748M | 879M | 494M |
| Total Debt | 1.51B | 442M | 38.3M |
HALO | NTRA | RARE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 11 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 55 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 39 | 34 | 100 | |
SMR RATING 1..100 | 12 | 92 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 45 | 58 | |
P/E GROWTH RATING 1..100 | 87 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 85 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (55) in the Biotechnology industry is in the same range as HALO (76) and is in the same range as RARE (79). This means that NTRA's stock grew similarly to HALO’s and similarly to RARE’s over the last 12 months.
NTRA's Profit vs Risk Rating (34) in the Biotechnology industry is in the same range as HALO (39) and is significantly better than the same rating for RARE (100). This means that NTRA's stock grew similarly to HALO’s and significantly faster than RARE’s over the last 12 months.
HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for NTRA (92) and is significantly better than the same rating for RARE (98). This means that HALO's stock grew significantly faster than NTRA’s and significantly faster than RARE’s over the last 12 months.
NTRA's Price Growth Rating (45) in the Biotechnology industry is in the same range as RARE (58) and is in the same range as HALO (63). This means that NTRA's stock grew similarly to RARE’s and similarly to HALO’s over the last 12 months.
HALO's P/E Growth Rating (87) in the Biotechnology industry is in the same range as NTRA (100) and is in the same range as RARE (100). This means that HALO's stock grew similarly to NTRA’s and similarly to RARE’s over the last 12 months.
| HALO | NTRA | RARE | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 85% | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 86% | 3 days ago 74% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 82% | 3 days ago 77% |
| MACD ODDS (%) | 3 days ago 82% | 3 days ago 80% | 3 days ago 75% |
| TrendWeek ODDS (%) | 3 days ago 70% | 3 days ago 83% | 3 days ago 75% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 83% | 3 days ago 72% |
| Advances ODDS (%) | 10 days ago 77% | 12 days ago 82% | 3 days ago 76% |
| Declines ODDS (%) | 6 days ago 68% | 3 days ago 80% | 12 days ago 80% |
| BollingerBands ODDS (%) | 3 days ago 79% | 3 days ago 78% | N/A |
| Aroon ODDS (%) | 3 days ago 75% | 3 days ago 84% | 3 days ago 74% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SFSLX | 25.87 | 0.34 | +1.33% |
| 1919 Financial Services C | |||
| SSRRX | 6.28 | 0.07 | +1.13% |
| Touchstone Small Company R6 | |||
| CRQSX | 13.07 | 0.13 | +1.00% |
| Catholic Rspnsbl Invst Equity Idx Ins | |||
| MLXIX | 28.26 | 0.28 | +1.00% |
| Catalyst Energy Infrastructure I | |||
| CWMCX | 64.23 | 0.34 | +0.53% |
| American Funds Washington Mutual 529C | |||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -1.06% | ||
| ISRG - NTRA | 57% Loosely correlated | -0.18% | ||
| VCYT - NTRA | 50% Loosely correlated | +1.78% | ||
| BSX - NTRA | 50% Loosely correlated | -0.72% | ||
| GKOS - NTRA | 47% Loosely correlated | +0.32% | ||
| GH - NTRA | 47% Loosely correlated | -0.72% | ||
More | ||||
RARE and
Correlation & Price change
A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.
| Ticker / NAME | Correlation To RARE | 1D Price Change % | ||
|---|---|---|---|---|
| RARE | 100% | +0.69% | ||
| CRNX - RARE | 53% Loosely correlated | +2.13% | ||
| COGT - RARE | 52% Loosely correlated | +13.52% | ||
| RVMD - RARE | 50% Loosely correlated | +2.26% | ||
| RNA - RARE | 49% Loosely correlated | +1.83% | ||
| DNLI - RARE | 49% Loosely correlated | +3.38% | ||
More | ||||